These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21209903)

  • 1. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
    Cizkova M; Cizeron-Clairac G; Vacher S; Susini A; Andrieu C; Lidereau R; Bièche I
    PLoS One; 2010 Dec; 5(12):e15647. PubMed ID: 21209903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
    Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
    Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.
    Cizkova M; Susini A; Vacher S; Cizeron-Clairac G; Andrieu C; Driouch K; Fourme E; Lidereau R; Bièche I
    Breast Cancer Res; 2012 Feb; 14(1):R28. PubMed ID: 22330809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
    Vasudevan KM; Barbie DA; Davies MA; Rabinovsky R; McNear CJ; Kim JJ; Hennessy BT; Tseng H; Pochanard P; Kim SY; Dunn IF; Schinzel AC; Sandy P; Hoersch S; Sheng Q; Gupta PB; Boehm JS; Reiling JH; Silver S; Lu Y; Stemke-Hale K; Dutta B; Joy C; Sahin AA; Gonzalez-Angulo AM; Lluch A; Rameh LE; Jacks T; Root DE; Lander ES; Mills GB; Hahn WC; Sellers WR; Garraway LA
    Cancer Cell; 2009 Jul; 16(1):21-32. PubMed ID: 19573809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
    Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
    Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
    Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach.
    Tozlu S; Girault I; Vacher S; Vendrell J; Andrieu C; Spyratos F; Cohen P; Lidereau R; Bieche I
    Endocr Relat Cancer; 2006 Dec; 13(4):1109-20. PubMed ID: 17158757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
    Wik E; Ræder MB; Krakstad C; Trovik J; Birkeland E; Hoivik EA; Mjos S; Werner HM; Mannelqvist M; Stefansson IM; Oyan AM; Kalland KH; Akslen LA; Salvesen HB
    Clin Cancer Res; 2013 Mar; 19(5):1094-105. PubMed ID: 23319822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
    Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
    Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
    Dumont AG; Dumont SN; Trent JC
    Chin J Cancer; 2012 Jul; 31(7):327-34. PubMed ID: 22640628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
    Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
    Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
    Tikoo A; Roh V; Montgomery KG; Ivetac I; Waring P; Pelzer R; Hare L; Shackleton M; Humbert P; Phillips WA
    PLoS One; 2012; 7(5):e36924. PubMed ID: 22666336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.